News
In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This ...
Then, in June, B.C.’s NDP government ended her treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback